-
公开(公告)号：US20090053205A1
公开(公告)日：2009-02-26
申请号：US12168641
申请日：2008-07-07
申请人： Ekambar Kandimalla , Tao Lan , Daqing Wang , Lakshmi Bhagat , Sudhir Agrawal
发明人： Ekambar Kandimalla , Tao Lan , Daqing Wang , Lakshmi Bhagat , Sudhir Agrawal
IPC分类号： A61K39/395 , C07H21/02 , A61K31/7105 , A61K39/00
CPC分类号： A61K39/39 , A61K31/7105 , A61K2039/55561 , C07H21/02 , C12N15/117 , C12N2310/17 , C12N2310/317 , C12N2310/3183 , C12N2310/51 , C12N2320/51
摘要： The invention relates to the therapeutic use of novel stabilized oligoribonucleotides as immune modulatory agents for immune therapy applications. Specifically, the invention provides novel RNA-based oligoribonucleotides with improved nuclease and RNase stability and that have immune modulatory activity through TLR7 and/or TLR8.
摘要翻译： 本发明涉及新型稳定的寡核糖核苷酸作为免疫治疗应用的免疫调节剂的治疗用途。 具体地，本发明提供了具有改进的核酸酶和核糖核酸酶稳定性并且通过TLR7和/或TLR8具有免疫调节活性的新型的基于RNA的寡核糖核苷酸。
-
公开(公告)号：US20120183530A1
公开(公告)日：2012-07-19
申请号：US13359714
申请日：2012-01-27
申请人： Ekambar Kandimalla , Tao Lan , Daqing Wang , Lakshmi Bhagat , Sudhir Agrawal
发明人： Ekambar Kandimalla , Tao Lan , Daqing Wang , Lakshmi Bhagat , Sudhir Agrawal
IPC分类号： A61K39/395 , A61P37/02 , A61K39/00 , A61K47/00 , C07H21/02 , A61K31/7088
CPC分类号： A61K39/39 , A61K31/7105 , A61K2039/55561 , C07H21/02 , C12N15/117 , C12N2310/17 , C12N2310/317 , C12N2310/3183 , C12N2310/51 , C12N2320/51
摘要： The invention relates to the therapeutic use of novel stabilized oligoribonucleotides as immune modulatory agents for immune therapy applications. Specifically, the invention provides novel RNA-based oligoribonucleotides with improved nuclease and RNase stability and that have immune modulatory activity through TLR7 and/or TLR8.
摘要翻译： 本发明涉及新型稳定的寡核糖核苷酸作为免疫治疗应用的免疫调节剂的治疗用途。 具体地，本发明提供了具有改进的核酸酶和核糖核酸酶稳定性并且通过TLR7和/或TLR8具有免疫调节活性的新型的基于RNA的寡核糖核苷酸。
-
公开(公告)号：US20110082186A1
公开(公告)日：2011-04-07
申请号：US12869185
申请日：2010-08-26
申请人： Sudhir Agrawal , Ekambar Kandimalla , Mallikarjuna Putta , Tao Lan , Lakshmi Bhagat , Daqing Wang , Dong Yu
发明人： Sudhir Agrawal , Ekambar Kandimalla , Mallikarjuna Putta , Tao Lan , Lakshmi Bhagat , Daqing Wang , Dong Yu
IPC分类号： C07H21/00 , C07H21/02 , C07H21/04 , A61K31/7088 , A61P35/00 , A61P37/00 , A61P29/00 , A61P31/00 , A61P37/08 , A61P11/06 , A61P31/04 , A61P31/12 , A61P33/00 , A61P31/10
CPC分类号： C12N15/1138 , C12N2310/11 , C12N2310/152 , C12N2310/321 , C12N2310/3519 , C12N2310/51
摘要： The inventors have examined the means for providing more efficacious gene expression blocking compounds. The inventors have discovered new structural features that surprisingly improve the efficacy of gene expression blocking molecules. These features include the presence of multiple 3′ ends and a linker at the 5′ ends. Surprisingly, these features improve the efficacy of the gene expression blocking compounds in a manner that decreases the compound's biologic instability. Even more surprisingly, this effect has been found to be applicable to both DNA and RNA oligonucleotide-based compounds and to have application in traditional antisense and RNAi technologies.
摘要翻译： 本发明人已经研究了提供更有效的基因表达阻断化合物的方法。 发明人已经发现了惊人地改善基因表达阻断分子的功效的新结构特征。 这些特征包括多个3'末端的存在和在5'端的接头。 令人惊讶的是，这些特征以降低化合物生物学不稳定性的方式提高了基因表达阻断化合物的功效。 更令人惊奇的是，这种效应已经被发现适用于基于DNA和RNA的寡核苷酸类化合物，并且应用于传统的反义和RNAi技术。
-
公开(公告)号：US08188261B2
公开(公告)日：2012-05-29
申请号：US12168641
申请日：2008-07-07
申请人： Ekambar Kandimalla , Tao Lan , Daqing Wang , Lakshmi Bhagat , Sudhir Agrawal
发明人： Ekambar Kandimalla , Tao Lan , Daqing Wang , Lakshmi Bhagat , Sudhir Agrawal
IPC分类号： C07H21/04
CPC分类号： A61K39/39 , A61K31/7105 , A61K2039/55561 , C07H21/02 , C12N15/117 , C12N2310/17 , C12N2310/317 , C12N2310/3183 , C12N2310/51 , C12N2320/51
摘要： The invention relates to the therapeutic use of novel stabilized oligoribonucleotides as immune modulatory agents for immune therapy applications. Specifically, the invention provides novel RNA-based oligoribonucleotides with improved nuclease and RNase stability and that have immune modulatory activity through TLR7 and/or TLR8.
摘要翻译： 本发明涉及新型稳定的寡核糖核苷酸作为免疫治疗应用的免疫调节剂的治疗用途。 具体地，本发明提供了具有改进的核酸酶和核糖核酸酶稳定性并且通过TLR7和/或TLR8具有免疫调节活性的新型的基于RNA的寡核糖核苷酸。
-
公开(公告)号：US08431544B1
公开(公告)日：2013-04-30
申请号：US12869209
申请日：2010-08-26
申请人： Sudhir Agrawal , Ekambar Kandimalla , Mallikarjuna Putta , Tao Lan , Lakshmi Bhagat , Daqing Wang , Dong Yu
发明人： Sudhir Agrawal , Ekambar Kandimalla , Mallikarjuna Putta , Tao Lan , Lakshmi Bhagat , Daqing Wang , Dong Yu
CPC分类号： C12N15/1138 , C12N2310/11 , C12N2310/152 , C12N2310/321 , C12N2310/3519 , C12N2310/51
摘要： The inventors have examined the means for providing more efficacious gene expression blocking compounds. The inventors have discovered new structural features that surprisingly improve the efficacy of gene expression blocking molecules. These features include the presence of multiple 3′ ends and a linker at the 5′ ends. Surprisingly, these features improve the efficacy of the gene expression blocking compounds in a manner that decreases the compound's biologic instability. Even more surprisingly, this effect has been found to be applicable to both DNA and RNA oligonucleotide-based compounds and to have application in traditional antisense and RNAi technologies.
摘要翻译： 本发明人已经研究了提供更有效的基因表达阻断化合物的方法。 发明人已经发现了惊人地改善基因表达阻断分子的功效的新结构特征。 这些特征包括多个3'末端的存在和在5'端的接头。 令人惊讶的是，这些特征以降低化合物生物学不稳定性的方式提高了基因表达阻断化合物的功效。 更令人惊奇的是，这种效应已经被发现适用于基于DNA和RNA的寡核苷酸类化合物，并且应用于传统的反义和RNAi技术。
-
6.发明授权Immune regulatory oligonucleotide (IRO) compounds to modulate toll-like receptor based immune response 有权免疫调节寡核苷酸（IRO）化合物调节基于类似受体的免疫应答公开(公告)号：US08399423B2
公开(公告)日：2013-03-19
申请号：US12244199
申请日：2008-10-02
申请人： Ekambar Kandimalla , Daqing Wang , Yukui Li , Dong Yu , FuGang Zhu , Lakshmi Bhagat , Sudhir Agrawal
发明人： Ekambar Kandimalla , Daqing Wang , Yukui Li , Dong Yu , FuGang Zhu , Lakshmi Bhagat , Sudhir Agrawal
CPC分类号： A61K48/00 , A61K31/711 , A61K39/12 , A61K2039/55561 , C12N2730/10134 , C12N2740/16011 , A61K2300/00
摘要： The invention provides the use of immune regulatory oligonucleotides (IRO) as antagonist of TLRs in the prevention and treatment of a disease caused by a pathogen, for example, a DNA or RNA virus.
摘要翻译： 本发明提供免疫调节寡核苷酸（IRO）作为TLR拮抗剂在预防和治疗由病原体例如DNA或RNA病毒引起的疾病中的用途。
-
公开(公告)号：US08383598B2
公开(公告)日：2013-02-26
申请号：US12140338
申请日：2008-06-17
申请人： Ekambar Kandimalla , Daqing Wang , Yukui Li , Dong Yu , FuGang Zhu , Lakshmi Bhagat , Sudhir Agrawal
发明人： Ekambar Kandimalla , Daqing Wang , Yukui Li , Dong Yu , FuGang Zhu , Lakshmi Bhagat , Sudhir Agrawal
CPC分类号： A61K48/00 , A61K31/7052 , A61K2039/55561 , Y02A50/414
摘要： The invention provides novel immune regulatory oligonucleotides (IRO) as antagonist of TLRs and methods of use thereof. These IROs have unique sequences that inhibit or suppress TLR-mediated signaling in response to a TLR ligand or TLR agonist. The methods may have use in the prevention and treatment of cancer, an autoimmune disorder, airway inflammation, inflammatory disorders, infectious disease, skin disorders, allergy, asthma or a disease caused by a pathogen.
-
8.发明申请公开(公告)号：US20100111937A1
公开(公告)日：2010-05-06
申请号：US12612413
申请日：2009-11-04
申请人： Ekambar Kandimalla , Mallikarjuna Putta , Lakshmi Bhagat , Daqing Wang , Dong Yu , Sudhir Agrawal
发明人： Ekambar Kandimalla , Mallikarjuna Putta , Lakshmi Bhagat , Daqing Wang , Dong Yu , Sudhir Agrawal
IPC分类号： A61K48/00 , C07H21/02 , A61K39/00 , A61K39/395 , A61K39/35 , A61K38/02 , A61P29/00 , A61P31/00
CPC分类号： A61K39/39 , A61K2039/55561 , C07H21/04 , C12N15/1138 , C12N2310/11 , Y02A50/401 , Y02A50/412 , Y02A50/414
摘要： Antisense oligonucleotide compounds, compositions and methods are provided for down regulating the expression of TLR5. The compositions comprise antisense oligonucleotides targeted to nucleic acids encoding TLR5. The compositions may also comprise antisense oligonucleotides targeted to nucleic acids encoding TLR5 in combination with other therapeutic and/or prophylactic compounds and/or compositions. Methods of using these compounds and compositions for down-regulating TLR5 expression and for prevention or treatment of diseases wherein modulation of TLR5 expression would be beneficial are provided.
摘要翻译： 提供反义寡核苷酸化合物，组合物和方法用于下调TLR5的表达。 组合物包含靶向编码TLR5的核酸的反义寡核苷酸。 组合物还可以包含靶向编码TLR5的核酸与其它治疗和/或预防化合物和/或组合物组合的反义寡核苷酸。 提供这些化合物和组合物用于下调TLR5表达和预防或治疗TLR5表达调节将是有益的疾病的方法。
-
9.发明申请IMMUNE REGULATORY OLIGONUCLEOTIDE (IRO) COMPOUNDS TO MODULATE TOLL-LIKE RECEPTOR BASED IMMUNE RESPONSE 有权免疫调节寡核苷酸（IRO）化合物，以调节基于类似感受器的免疫应答公开(公告)号：US20090081198A1
公开(公告)日：2009-03-26
申请号：US12140338
申请日：2008-06-17
申请人： Ekambar Kandimalla , Daqing Wang , Yukui Li , Dong Yu , FuGang Zhu , Lakshmi Bhagat , Sudhir Agrawal
发明人： Ekambar Kandimalla , Daqing Wang , Yukui Li , Dong Yu , FuGang Zhu , Lakshmi Bhagat , Sudhir Agrawal
IPC分类号： A61K39/395 , A61K31/7052 , A61K38/02 , A61P37/06 , A61K38/16 , A61K39/00
CPC分类号： A61K48/00 , A61K31/7052 , A61K2039/55561 , Y02A50/414
摘要： The invention provides novel immune regulatory oligonucleotides (IRO) as antagonist of TLRs and methods of use thereof. These IROs have unique sequences that inhibit or suppress TLR-mediated signaling in response to a TLR ligand or TLR agonist. The methods may have use in the prevention and treatment of cancer, an autoimmune disorder, airway inflammation, inflammatory disorders, infectious disease, skin disorders, allergy, asthma or a disease caused by a pathogen.
摘要翻译： 本发明提供作为TLR拮抗剂的新型免疫调节寡核苷酸（IRO）及其使用方法。 这些IRO具有独特的序列，其响应于TLR配体或TLR激动剂抑制或抑制TLR介导的信号传导。 该方法可用于预防和治疗癌症，自身免疫性疾病，气道炎症，炎症性疾病，感染性疾病，皮肤病，变态反应，哮喘或由病原体引起的疾病。
-
公开(公告)号：US20080292648A1
公开(公告)日：2008-11-27
申请号：US11954726
申请日：2007-12-12
申请人： Ekambar Kandimalla , Mallikarjuna Putta , Dong Yu , Lakshmi Bhagat , Daqing Wang , Sudhir Agrawal
发明人： Ekambar Kandimalla , Mallikarjuna Putta , Dong Yu , Lakshmi Bhagat , Daqing Wang , Sudhir Agrawal
CPC分类号： C12N15/117 , C12N2310/17 , C12N2310/315 , C12N2310/317 , C12N2310/3183 , C12N2310/321 , C12N2310/336 , C12N2310/3521
摘要： The invention provides novel oligonucleotide-based compounds that individually provide distinct immune response profiles through their interactions as agonists with TLR9. The TLR9 agonists according to the invention are characterized by specific and unique chemical modifications, which provide their distinctive immune response activation profiles.
摘要翻译： 本发明提供了新的基于寡核苷酸的化合物，其通过作为具有TLR9的激动剂的相互作用单独提供不同的免疫应答谱。 根据本发明的TLR9激动剂的特征在于特异性和独特的化学修饰，其提供其独特的免疫应答活化谱。
-
-
-
-
-
-
-
-
-
搜索结果
63 条记录 (耗时 0.031 秒)
